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Background: Small cell carcinoma of the rectum is a rare neoplasm with scant literature to guide treatment. We
used the Surveillance Epidemiology and End Results (SEER) database to investigate the role of radiation therapy in
the treatment of this cancer.
Methods: The SEER database (National Cancer Institute) was queried for locoregional cases of small cell rectal
cancer. Years of diagnosis were limited to 1988–2010 (most recent available) to reduce variability in staging criteria
or longitudinal changes in surgery and radiation techniques. Two month conditional survival was applied to
minimize bias by excluding patients who did not survive long enough to receive cancer-directed therapy. Patient
demographics between the RT and No_RT groups were compared using Pearson Chi-Square tests. Overall survival was
compared between patients who received radiotherapy (RT, n = 43) and those who did not (No_RT, n = 28) using the
Kaplan-Meier method. Multivariate Cox proportional hazards model was used to evaluate important covariates.
Results: Median survival was significantly longer for patients who received radiation compared to those who were not
treated with radiation; 26 mo vs. 8 mo, respectively (log-rank P = 0.009). We also noted a higher 1-year overall survival
rate for those who received radiation (71.1% vs. 37.8%). Unadjusted hazard ratio for death (HR) was 0.495 with the use
of radiation (95% CI 0.286-0.858). Among surgery, radiotherapy, sex and age at diagnosis, radiation therapy was the only
significant factor for overall survival with a multivariate HR for death of 0.393 (95% CI 0.206-0.750, P = 0.005).
Conclusions: Using SEER data, we have identified a significant survival advantage with the use of radiation therapy in
the setting of rectal small cell carcinoma. Limitations of the SEER data apply to this study, particularly the lack of
information on chemotherapy usage. Our findings strongly support the use of radiation therapy for patients with
locoregional small cell rectal cancer.Background
Neuroendocrine neoplasias (NEN) arise from neural and
endocrine cell types and can occur all throughout the
body. NEN are broadly grouped into pulmonary and
extrapulmonary primary sites and encompass a hetero-
geneous class of malignancies that vary widely in their
clinical presentations and characteristics. The number of
different iterations of NEN that arise as a function of
primary site, grade and clinical presentation com-
pounded by their relative infrequency has made clinical
trial execution difficult and slowed the pace at which
outcomes can be improved for the many subtypes [1-3].* Correspondence: Kevin.Du@nyumc.org
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unless otherwise stated.Grade I/II NEN are by definition neuroendocrine tumors
(NET). Some of the literature use the term NET to refer
more broadly to NEN, which encompass all grades of
neuroendocrine neoplasms. The more aggressive and
poorly differentiated grade III neuroendrocrine carcin-
omas (NEC) are further subdivided into small cell car-
cinomas (SCC) and large cell carcinomas (LCC).
Surveillance, Epidemiology and End Results (SEER)
studies examining NEN epidemiology revealed an inci-
dence rate of 5.25 and 5.76 per 100,000 for the 2000–
2004 and 2003–2007 periods, respectively [4,5]. Both of
these studies note a greater than four-fold increase in
the incidence of NEN for the data available since 1973,
which the authors of the studies attribute to improved
diagnostic capabilities and greater disease awareness.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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had median survival times of 124 and 64 months,
respectively, while those diagnosed with poorly differen-
tiated tumors (such as SCC or LCC) had a 10 month
median survival time [5]. The stark difference between
mortality rates of low and high grade NEN highlights
the importance of establishing more accurate and con-
sistent grading criteria to guide future treatments, distin-
guish between indolent and aggressive subtypes and
provide meaningful prognostic information.
Extrapulmonary GI NEN as a group make up 61% of
all NEN diagnoses, with the rectum being the most
common site (17.7%), followed by the small intestines
(17.3%) and colon (10.1%) [4]. Amongst the more
aggressive and rare GI SCC, the most common site of
incidence is the esophagus (53%) followed by the colon
(13%), stomach (11%), gall bladder (8.4%) and rectum
(7.3%) [4,6]. SCC of the rectum are aggressive and rare
tumors compromising less than 1% of all GI neoplasms,
with reported median survival ranging from 7 to
11 months and estimated five year survival rates of 8-
15% [5,7-12]. Due to its low incidence, there is a paucity
of literature to guide treatment and we are currently
limited to case reports and small retrospective studies.
Treatments for extrapulmonary GI SCC have been
guided by extrapolating from treatment modalities used
for small cell lung cancer [2,9,13]. Nonetheless, in the
published literature there was tremendous variation in
treatment approaches, outcomes and follow-up informa-
tion. Given the scarcity of literature and rare incidence
of rectal SCC, we performed a SEER database analysis to
understand the potential role of radiotherapy in the
treatment of this malignancy.
Methods
The SEER database (National Cancer Institute) was
queried with SEER*Stat8.1.2 software for rectal small cell
cancer cases. In order to exclude patients with distant
metastatic disease, we restricted the search to locoregio-
nal cases by using the “SEER Historic Stage A” variable.
Years of diagnosis were restricted to 1988–2010, in
order to reduce bias or error due to variability in sta-
ging/grading criteria and longitudinal changes in chemo-
therapy, surgery or radiation treatment techniques.
Radiation in the RT group was limited to external beam
radiation therapy for all cases. Surgical procedures were
grouped based on the extent of resection. A two month
conditional survival was applied to minimize bias by
excluding patients who did not survive long enough to
receive cancer-directed therapy. Overall survival was
compared between patients who received radiation (RT)
and those who did not (No_RT) using the Kaplan-Meier
method. Multivariate Cox proportional hazards statistical
modeling was used to evaluate important covariates, withAJCC Stage as a stratification variable. Patient demograph-
ics between the RT and No_RT groups were compared
using Pearson Chi-Square tests.
Results
The SEER database included 71 patients that fit our study
criteria. This patient cohort had 43 patients treated with
radiation (RT group) and 28 patients without radiation
(No_RT group). There were no significant difference
between the RT and No_RT groups when considering
demographic factors such as sex, race and stage
(Table 1). There were also no statistical differences be-
tween patient location, marital status and year of diag-
nosis (data not shown). We did note a statistically
significant difference in the sequence number in which
rectal SCC was diagnosed; patients in the No_RT arm
had a significant portion of rectal SCC diagnoses follow-
ing another malignancy. Between the two arms of the
study, the RT group received surgery 32.6% of the time,
while the No_RT group received surgery 50% of the time,
but this was not statistically significant with a p-value of
0.142. Chemotherapy regimen was not available through
the SEER database.
Overall survival between the two groups differed sig-
nificantly, with median survival of 26 months for the RT
group versus 8 months for the No_RT group (P = 0.009)
(Figure 1). Patients who were treated with radiation had
a 1 year overall survival rate of 71.1% compared to
37.8% for patients who were not treated with radiation.
The unadjusted hazard ratio (HR) for death for patients
that received radiation was 0.495 (95% CI 0.286-0.858).
To understand how age at diagnosis, sex, surgery, and
radiation affect survival, we performed univariate and
multivariate cox proportional hazards modeling using
AJCC stage as a stratification variable (Table 2). Radi-
ation therapy was the only significant factor for overall
survival, with a multivariate HR for death of 0.393 (95%
CI 0.206-0.750, P = 0.005). We did not observe a signifi-
cant survival benefit from the use of surgery.
Discussion
Rectal small cell carcinoma is an aggressive and rare
cancer with no standard treatment protocol. In the
literature, and consistent with our own SEER analysis,
the overall median survival for rectal SCC cases has
ranged from 7 to 11 months [5,7-12]. Small cell lung
carcinoma (SCLC) has primarily been treated with plat-
inum based chemotherapies in conjunction with thoracic
radiotherapy, and in some cases, prophylactic cranial
irradiation [13-17]. However, SCLC treatments and out-
comes may only go so far in translating to extrapulmonary
SCC treatment. Platinum based chemotherapeutic ap-
proaches similar to those used in lung SCC have been
the mainstay of treatment for many reported cases of
Table 1 Patient demographics
No_RT RT Pearson chi-square
N % N % P
Totals (n=71) 28 43
Sex Male 16 57.10% 24 55.80% 0.912
Female 12 42.90% 19 44.20%
Race White 25 89.30% 40 93.00% 0.458
Black 3 10.70% 2 4.70%
Other 0 0.00% 1 2.30%
Stage 0 1 3.60% 1 2.30% 0.584
I 8 28.60% 14 32.60%
II 7 25.00% 9 20.90%
III 9 32.10% 18 41.90%
Unknown 3 10.70% 1 2.30%
Cancer diagnosis sequence number One primary only 18 64.30% 39 90.70% 0.013
1st of 2 or more 0 0.00% 1 2.30%
2nd of 2 or more 9 32.10% 2 4.70%
3rd of 3 or more 0 0.00% 1 2.30%
5th of 5 or more 1 3.60% 0 0.00%
Radiation None 27 96.40% 0 0.00% N/A
Beam radiation 0 0.00% 43 100.00%
Recommended, unknown if administered 1 3.60% 0 0.00%
Surgery None/Unknown 14 50.00% 29 67.40% 0.142
Surgery given 14 50.00% 14 32.60%
Radiation sequence with surgery No radiation and/or cancer-directed surgery 28 100.00% 29 67.40% N/A
Radiation prior to surgery 0 N/A 2 4.70%
Radiation after surgery 0 N/A 12 27.90%
Surgery Groups No/Unknown 14 50.00% 29 67.40% 0.34
Local surgery 7 25.00% 7 16.30%
Extended surgery 7 25.00% 7 16.30%
Reason no cancer-directed surgery Surgery performed 14 50.00% 14 32.60% 0.226
Not recommended 10 35.70% 23 53.50%
Not recommended, contraindicated due to other conditions 0 0.00% 2 4.70%
Recommended but not performed, unknown reason 4 14.30% 2 4.70%
Recommended but not performed, patient refused 0 0.00% 1 2.30%
Recommended, unknown if performed 0 0.00% 1 2.30%
The radiotherapy (RT) and no radiotherapy (No_RT) arms of the study were stratified based on sex, age, diagnostic sequence and treatments received. The two
groups were subject to Pearson’s Chi-square statistical analysis. For the surgical categories: “No/Unknown” includes codes for: No surgery, incisional biopsy, bypass
surgery only, surgery of regional site without primary site, unknown if surgery done. “Local surgery” includes codes for: local tumor excision, anterior/posterior
resection, wedge or segmental resection, partial proctectomy, surgery NOS, polypectomy, excisional biopsy. “Extended surgery” includes codes for: Pull through
with coloanal anastamosis, APR complete proctectomy, surgeries with partial or total removal of other organs.
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calized disease in combination with chemotherapy or radio-
therapy, but strong correlative benefits have not been
established [2,9,13,23,24]. Radiotherapy used to treat extra-
pulmonary SCCs, with or without concurrent chemother-
apy, has been reported to result in a clinical response in
many cases [6,13,24-28]. Of the 12 patients who receivedradiotherapy for GI SCC reported by Brenner et al., 11 out
of 12 saw a partial/complete response or residual disease,
with a survival of 3–17 months [6]. A larger 127 patient
study of limited stage esophageal SCC demonstrated a
33 month median survival for patients who received che-
moradiotherapy, while those who received surgery and
chemotherapy had a 17.5 month median survival [26].
Figure 1 Kaplan-Meier plot of rectal small cell carcinoma cases treated with or without radiation. Rectal small cell carcinoma cases stratified by
radiation treatment from the SEER database were subject to Kaplan-Meier analysis for retrospective survival benefit analysis. The no radiation
therapy (No_RT) arm consisted of 28 cases. The group that received radiation therapy (RT) consisted of 43 cases.
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and found a broad range of treatment strategies and pa-
tient outcomes (Table 3). Although some rectal SCC cases
were treated with chemotherapy regimens similar to that
of lung SCC, only a small portion of reported cases fell
into that category. The most commonly employed treat-
ment appeared to be surgery alone, followed by surgery
and chemotherapy and lastly chemoradiotherapy. There
were only three reported cases in which trimodality ther-
apy was used. In some cases, radiotherapy was used for
palliative measures in the setting of metastatic disease.
The overall survival times in these case studies varied
widely, and this may be partly due to differences in tumorTable 2 Cox Proportional Hazards Model with AJCC Stage as
Variable Level No_RT N (%) RT N (%)
Radiation No_RT 28 (100%) N/A
RT N/A 43 (100%)
Surgery No_Surgery 14 (32.6%) 29 (67.4%)
Surgery 14 (50.0%) 14 (50.0%)
Sex Male 16 (40.0%) 24 (60.0%)
Female 12 (38.7%) 19 (61.3%)
Variable Level No_RT Mean (SD) RT Mean (SD)
Age at diagnosis Continuous per year 62.4 (16.6) 58.9 (14.6)
Patients who received RT or no RT were subject to univariate and multivariate cox p
with AJCC stage stratification.stage at diagnosis. Although this literature search gives
us a snapshot of the variety of treatment strategies on a
case-by-case basis, it lacks the statistical power to guide
treatment for future cases.
We cannot rule out the benefit of surgery from this
study due to small sample sizes and insufficient power.
It is also important to consider the limitations of using
this retrospective SEER analysis to draw strong correla-
tive conclusions. There is no chemotherapy data avail-
able in our SEER cohort, so we cannot account for any
effects arising from differences in chemotherapy regi-
mens. We were not able to determine from the SEER
database whether radiation given to the RT group wasstratification variable
Univariate HR 95% CI P Multivariate HR 95% CI P
Referent Referent
0.43 0.24 - 0.77 0.01 0.393 0.21 - 0.75 0.01
Referent Referent
0.80 0.43 - 1.49 0.47 0.53 0.26 - 1.08 0.08
Referent Referent
0.91 0.49 - 1.70 0.76 0.90 0.47 - 1.74 0.76
Univariate HR 95% CI P Multivariate HR 95% CI P
1.02 1.0 - 1.04 0.14 1.01 0.98 - 1.03 0.32
roportional hazards modeling (radiation, surgery, sex and age of diagnosis)
Table 3 Summary of recent rectal small cell carcinoma case reports
Age Sex Chemotherapy Radiation Surgery Metastasis Outcome Reference
29 F ETP+CDDP RT (60Gy) tumor resection (unspecified) none >42 mo [29]
34 M ETP+CBDCA RT (unspecified) proctocolectomy none >18 mo [30]
68 F ETP+CDDP RT (39.6Gy) abdominoperineal resection liver 4 mo [31]
51 M CPM+DXR+vincristine
+CBDCA+ETP
RT (30Gy) - none >72 mo [17]




- CNS and liver 17 mo [19]
58 M ETP+CDDP RT (pallative, cranial
50.4Gy)
- CNS and liver 3 mo [32]
62 M ETP+CDDP RT (50Gy/2Gy
fractions)
- liver 12 mo [33]
45 F - RT (pallative) - bone and liver 3 mo [34]
68 M - RT (unspecified) - unknown 12 mo [35]
83 M - RT (unspecified) - none >3 mo [35]
68 F chemotherapy
(unspecified)
- - liver, lymph nodes >4.5 mo [35]
46 F chemotherapy
(unspecified)
- colectomy liver, lymph nodes 3 mo [35]
40 F ETP+CPM+DXR - lower anterior resection CNS 6 mo [20]
69 M DXR, 5-FU+CDDP, ETP
+CDDP
- rectal amputation, lymphadenectomy unknown >16 mo [36]
36 M CDDP+irinotecan - proctocolectomy lymph nodes >8 mo [37]
46 M ETP+CDDP - liver resection and abdominoperineal
resection
liver >48 mo [38]
74 M FOLFOX+bevacizumab - rectosigmoidectomy liver 3 mo [39]





83 F - - colectomy liver, lymph nodes >26 mo [35]
50 F - - radical resection of tumor unknown 8 mo [40]
78 M - - endoscopic submucosal dissection lymph nodes 6 mo [41]
47 M - - rectal amputation, lymphadenectomy lymph nodes >37 mo [42]
63 M - tumor resection (unspecified) liver, lymph nodes 10 mo [43]





46 F - - diverting colostomy liver, lymph nodes unknown [21]
74 M - - tumor resection (unspecified) 2 mo [21]
80 F - - colectomy none unknown [35]
34 F - - colectomy none >6 mo [35]
74 F - - colectomy liver, lymph nodes 3 mo [35]
Age, sex, treatment, metastasis and outcome from rectal SCC cases found in the literature. Abbreviations: RT, radiation therapy. Gy, gray. DXR, doxorubicin. 5-FU,
5-fluorouracil. CDDP, cisplatin. CMP, cyclophosphamide. ETP, etoposide. CBDCA, carboplatin. FOLFOX, folinic acid, 5-FU and oxaliplatin chemotherapy regiment.
CNS, central nervous system.
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a significantly greater proportion of the patients had a his-
tory of other prior malignancy before receiving a diagnosis
of rectal SCC; these patients may have received previous
radiation treatment to the pelvic area or previous chemo-
therapy. Despite the inherent limitations with using theSEER database, this study provides evidence for the benefit
of radiation therapy for the treatment of rectal SCC.
Conclusions
Given the scarcity of literature, we performed an analysis of
rectal SCC patients entered into the SEER database from
Modrek et al. Radiation Oncology  (2015) 10:101 Page 6 of 71988 to 2010 in the United States. We were interested
in the effect of radiation therapy and surgery on overall
survival in rectal SCC. Radiation has been shown to
confer a benefit in other extrapulmonary SCCs and in
lung SCC [6,9,13-16,26]. And, the role of surgery
in extrapulmonary SCC is controversial [2,9,13,23,24].
Our analysis revealed a significant survival benefit to
patients that received radiotherapy, with or without sur-
gery. Radiation therapy was the strongest prognostic
variable amongst sex, age at diagnosis or surgery for
overall survival. Although this SEER analysis has limita-
tions, such as lack of chemotherapy information and
retrospective study design, it provides guidance on how
to manage this rare and aggressive cancer. These find-
ings may also influence future prospective studies to
establish a standard treatment regimen for rectal SCC.Competing interests
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